Found: 1870
Select item for more details and to access through your institution.
Long-term renoprotective effect of luseogliflozin in type 2 diabetes patients: CHikushi Anti-diabetes mellitus Trial-Lusefi (CHAT-Lu).
- Published in:
- Drug Discoveries & Therapeutics, 2024, v. 18, n. 6, p. 336, doi. 10.5582/ddt.2024.01086
- By:
- Publication type:
- Article
One or two? Comparison of the cardiorenal effects between combination therapy and monotherapy with SGLT2i or GLP1RA.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 806, doi. 10.1111/dom.16078
- By:
- Publication type:
- Article
Early combination therapy with SGLT2i and GLP‐1 RA or dual GIP/GLP‐1 RA in type 2 diabetes.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 468, doi. 10.1111/dom.16077
- By:
- Publication type:
- Article
Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 574, doi. 10.1111/dom.16049
- By:
- Publication type:
- Article
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients.
- Published in:
- Biomedicines, 2024, v. 12, n. 12, p. 2783, doi. 10.3390/biomedicines12122783
- By:
- Publication type:
- Article
New Advances in Cardiovascular Drugs: A Celebration of the 90th Birthday of Professor Akira Endo.
- Published in:
- Biomedicines, 2024, v. 12, n. 12, p. 2716, doi. 10.3390/biomedicines12122716
- By:
- Publication type:
- Article
Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Addressing free fatty acid receptor 1 (FFAR1) activation using supervised molecular dynamics.
- Published in:
- Journal of Computer-Aided Molecular Design, 2020, v. 34, n. 11, p. 1181, doi. 10.1007/s10822-020-00338-6
- By:
- Publication type:
- Article
Carbon 14 and Carbon 13 Syntheses of Velagliflozin.
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2024, v. 67, n. 5, p. 180, doi. 10.1002/jlcr.4091
- By:
- Publication type:
- Article
Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin ( JNJ-28431754).
- Published in:
- Journal of Labelled Compounds & Radiopharmaceuticals, 2017, v. 60, n. 13, p. 616, doi. 10.1002/jlcr.3542
- By:
- Publication type:
- Article
Protection of the kidney with sodium-glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials.
- Published in:
- Clinical & Experimental Nephrology, 2019, v. 23, n. 3, p. 304, doi. 10.1007/s10157-018-1673-0
- By:
- Publication type:
- Article
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
- Published in:
- Journal of Pharmacy & Pharmacology, 2014, v. 66, n. 7, p. 975, doi. 10.1111/jphp.12223
- By:
- Publication type:
- Article
Sodium glucose cotransporter 2 in mesangial cells and retinal pericytes and its implications for diabetic nephropathy and retinopathy.
- Published in:
- Glycobiology, 2017, v. 27, n. 8, p. 691, doi. 10.1093/glycob/cwx047
- By:
- Publication type:
- Article
The role of SGLT2 inhibitors in heart failure.
- Published in:
- American Journal of Pharmacotherapy & Pharmaceutical Sciences, 2022, p. 1, doi. 10.25259/AJPPS_5_2021
- By:
- Publication type:
- Article
Predictors Of Kidney Function Outcomes In Type 2 Diabetes Mellitus Patients With Chronic Heart Failure Treated With Dapagliflosin.
- Published in:
- E Journal of Cardiovascular Medicine, 2023, v. 11, p. 1
- By:
- Publication type:
- Article
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2021, v. 30, n. 4, p. 336, doi. 10.7570/jomes21061
- By:
- Publication type:
- Article
The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
- Published in:
- Journal of Obesity & Metabolic Syndrome, 2019, v. 28, n. 1, p. 18, doi. 10.7570/jomes.2019.28.1.18
- By:
- Publication type:
- Article
SGLT2 inhibitors.
- Published in:
- SA Pharmaceutical Journal Incorporating Pharmacy Management, 2018, v. 85, n. 1, p. 72
- By:
- Publication type:
- Article
Pharmacological effect of sodium-glucose cotransporter 2 inhibitors in reducing the incidence of nephrolithiasis.
- Published in:
- Journal of Parathyroid Disease, 2023, v. 11, n. 1, p. 1, doi. 10.34172/jpd.2023.11220
- By:
- Publication type:
- Article
Anti-Hyperglycemic Effect of Magnesium-Enhanced Alkaline-Reduced Water on High Glucose-Induced Oxidative Stress in Renal Tubular Epithelial Cells.
- Published in:
- Processes, 2022, v. 10, n. 5, p. 919, doi. 10.3390/pr10050919
- By:
- Publication type:
- Article
SGLT2 Inhibitors: A Noval Therapuetic Agent in the Treatment of Diabetic Kidney Disease.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2020, v. 10, n. 6, p. 203, doi. 10.22270/jddt.v10i6.4532
- By:
- Publication type:
- Article
Pharmacophore Modeling Study of Sodium Glucose Co-Transporter-2 (Sglt2) Inhibitor for Antidiabetic Activity.
- Published in:
- Journal of Drug Delivery & Therapeutics, 2020, v. 10, n. 1A, p. 78
- By:
- Publication type:
- Article
A longitudinal follow-up study of a type 2 diabetes "lost to follow-up" cohort – positive effect on glycaemic control after changes in medication.
- Published in:
- International Journal of Circumpolar Health, 2020, v. 79, n. 1, p. 1, doi. 10.1080/22423982.2020.1773127
- By:
- Publication type:
- Article
SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 35, doi. 10.1007/s40256-021-00486-6
- By:
- Publication type:
- Article
Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 69, doi. 10.1007/s40256-021-00484-8
- By:
- Publication type:
- Article
Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 6, p. 701, doi. 10.1007/s40256-021-00503-8
- By:
- Publication type:
- Article
Blood Pressure-Lowering Effect of Newer Antihyperglycemic Agents (SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors).
- Published in:
- American Journal of Cardiovascular Drugs, 2021, v. 21, n. 2, p. 123, doi. 10.1007/s40256-020-00423-z
- By:
- Publication type:
- Article
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention.
- Published in:
- American Journal of Cardiovascular Drugs, 2020, v. 20, n. 5, p. 419, doi. 10.1007/s40256-020-00397-y
- By:
- Publication type:
- Article
Cardiovascular Protection with Anti-hyperglycemic Agents.
- Published in:
- American Journal of Cardiovascular Drugs, 2019, v. 19, n. 3, p. 249, doi. 10.1007/s40256-019-00325-9
- By:
- Publication type:
- Article
The Emerging Role of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes. Focus on Dapagliflozin.
- Published in:
- Romanian Journal of Diabetes Nutrition & Metabolic Diseases, 2016, v. 23, n. 1, p. 113, doi. 10.1515/rjdnmd-2016-0014
- By:
- Publication type:
- Article
Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07250-z
- By:
- Publication type:
- Article
The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05704-y
- By:
- Publication type:
- Article
Direct evidence of proximal tubular proliferation in early diabetic nephropathy.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-04880-1
- By:
- Publication type:
- Article
Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-94945-4
- By:
- Publication type:
- Article
Use of sodium–glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.
- Published in:
- Geriatrics & Gerontology International, 2018, v. 18, n. 1, p. 108, doi. 10.1111/ggi.13149
- By:
- Publication type:
- Article
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1213473
- By:
- Publication type:
- Article
Development of an immunoassay for the simultaneous detection of GADA and ZnT8A in autoimmune diabetes using a ZnT8/GAD65 chimeric molecule.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 1, doi. 10.3389/fimmu.2023.1219857
- By:
- Publication type:
- Article
Case report: A case of Rabson-Mendenhall syndrome: long-term follow-up and therapeutic management with empagliflozin.
- Published in:
- Frontiers in Genetics, 2024, p. 1, doi. 10.3389/fgene.2024.1414451
- By:
- Publication type:
- Article
Use of SGLT2 Inhibitors in Older Adults: Scientific Evidence and Practical Aspects.
- Published in:
- Drugs & Aging, 2020, v. 37, n. 6, p. 399, doi. 10.1007/s40266-020-00757-y
- By:
- Publication type:
- Article
Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data.
- Published in:
- Drugs & Aging, 2020, v. 37, n. 5, p. 393, doi. 10.1007/s40266-020-00759-w
- By:
- Publication type:
- Article
Perioperative genitourinary infection associated with sodium-glucose co-transporter 2 inhibitor use.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Canagliflozin and Cardiovascular disease- results of the CANVAS trial.
- Published in:
- Journal of Community Hospital Internal Medicine Perspectives (JCHIMP), 2018, v. 8, n. 5, p. 267, doi. 10.1080/20009666.2018.1521245
- By:
- Publication type:
- Article
Additive antiproteinuric effect of pentoxifylline in patients with diabetic nephropathy under angiotensin receptor blockade: A short-term, randomized, and controlled trial.
- Published in:
- National Journal of Physiology, Pharmacy & Pharmacology, 2022, v. 12, n. 6, p. 823, doi. 10.5455/njppp.2022.12.04159202221042022
- By:
- Publication type:
- Article
Editorial: Diabetes and Heart Failure: Pathogenesis and Novel Therapeutic Approaches.
- Published in:
- Frontiers in Physiology, 2019, p. N.PAG, doi. 10.3389/fphys.2019.00253
- By:
- Publication type:
- Article
Myocyte [Na<sup>+</sup>]i Dysregulation in Heart Failure and Diabetic Cardiomyopathy.
- Published in:
- Frontiers in Physiology, 2018, p. 1, doi. 10.3389/fphys.2018.01303
- By:
- Publication type:
- Article
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 1, doi. 10.3389/fendo.2023.1144838
- By:
- Publication type:
- Article
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 1, doi. 10.3389/fendo.2023.1111984
- By:
- Publication type:
- Article
The effects of Sodium-glucose cotransporter 2 inhibitors on adipose tissue in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
- Published in:
- Frontiers in Endocrinology, 2023, v. 14, p. 1, doi. 10.3389/fendo.2023.1115321
- By:
- Publication type:
- Article